APA

Hamid O., Robert C., Daud A., Hodi F. S., Hwu W., Kefford R., Wolchok J. D., Hersey P., Joseph R. W., Weber J. S., Dronca R., Gangadhar T. C., Patnaik A., Zarour H., Joshua A. M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P. C., Chmielowski B., Ebbinghaus S. W., Li X. N., Kang S. P. & Ribas A. (20130725). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. : The New England journal of medicine.

Chicago

Hamid Omid, Robert Caroline, Daud Adil, Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D, Hersey Peter, Joseph Richard W, Weber Jeffrey S, Dronca Roxana, Gangadhar Tara C, Patnaik Amita, Zarour Hassane, Joshua Anthony M, Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C, Chmielowski Bartosz, Ebbinghaus Scot W, Li Xiaoyun Nicole, Kang S Peter and Ribas Antoni. 20130725. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. : The New England journal of medicine.

Harvard

Hamid O., Robert C., Daud A., Hodi F. S., Hwu W., Kefford R., Wolchok J. D., Hersey P., Joseph R. W., Weber J. S., Dronca R., Gangadhar T. C., Patnaik A., Zarour H., Joshua A. M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P. C., Chmielowski B., Ebbinghaus S. W., Li X. N., Kang S. P. and Ribas A. (20130725). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. : The New England journal of medicine.

MLA

Hamid Omid, Robert Caroline, Daud Adil, Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D, Hersey Peter, Joseph Richard W, Weber Jeffrey S, Dronca Roxana, Gangadhar Tara C, Patnaik Amita, Zarour Hassane, Joshua Anthony M, Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C, Chmielowski Bartosz, Ebbinghaus Scot W, Li Xiaoyun Nicole, Kang S Peter and Ribas Antoni. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. : The New England journal of medicine. 20130725.